CT-5252

CT-5252
Clinical data
Other names	CT5252; Methyl-12-bromo-8,9-didehydro-2,3β-dihydro-6-methyl-10,11-secoergoline-8-carboxylate
Drug class	Simplified/partial LSD analogue
Chemical and physical data
Formula	C17H21BrN2O2
Molar mass	365.271 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C1=CCC(CC2CNc3ccc(Br)cc23)N(C)C1;
	InChI InChI=1S/C17H21BrN2O2/c1-20-10-11(17(21)22-2)3-5-14(20)7-12-9-19-16-6-4-13(18)8-15(12)16/h3-4,6,8,12,14,19H,5,7,9-10H2,1-2H3; Key:POWSHADSWSCVJU-UHFFFAOYSA-N;

CT-5252 is a tryptamine-like less-rigid analogue of lysergic acid diethylamide (LSD).^[1]^[2]^[3]^[4] It is a 10,11-secoergoline; that is, an ergoline in which the covalent bond between the 10 and 11 positions of the ergoline ring system has been broken to unconstrain the structure.^[2]^[3]^[4] The drug produces specific LSD-like behavioral changes in guinea pigs but with only about 1/48th the potency of LSD.^[1]^[2]^[3] It also causes seizures at slightly higher doses than those that cause LSD-like effects.^[3] CT-5252 was first described in the scientific literature in 1969.^[4]^[3] The analogue of CT-5252 with an N,N-diethyl-carboxamide moiety on the tetrahydropyridine ring instead of the carboxylate group (i.e., more analogous to LSD) has also been assessed and described.^[3]

Quick facts Clinical data, Other names ...

See also